中药治疗失血性休克的系统评价与Meta分析
该系统评价纳入15项随机对照试验共1076例失血性休克患者,比较中药联合常规治疗与单用常规治疗的效果。Meta分析显示联合治疗可降低病死率(RR=0.24,95%CI:0.13-0.46,P<0.0001)和多器官功能障碍综合征(MODS)发生率(RR=0.47,95%CI:0.34-0.66,P<0.00001),并改善血压、心率和尿量,未报告严重不良事件,但纳入试验方法学质量较低,结论需谨慎解读。
要点
- 中药联合常规治疗可能降低失血性休克患者病死率(RR=0.24,95%CI:0.13-0.46)。
- 联合治疗可能降低MODS发生率(RR=0.47,95%CI:0.34-0.66)。
- 联合治疗可升高血压、调节心率、增加尿量,但证据质量低。
核心结论
- 中药联合常规治疗对失血性休克患者可能更有效,但受纳入试验方法学质量低的限制,结论需谨慎解读。
研究设计与样本
- 系统评价与Meta分析,检索Web of ScienceDirect、PubMed、Cochrane Library、EMBASE、CBM、CNKI和WanFang数据库至2015年1月,纳入15项RCT共1076例患者。
主要发现
- 与单用常规治疗相比,中药联合常规治疗降低病死率(RR=0.24,95%CI:0.13-0.46,P<0.0001)。
- 联合治疗降低MODS发生率(RR=0.47,95%CI:0.34-0.66,P<0.00001)。
- 联合治疗升高血压(MD=8.83,95%CI:6.82-10.84,P<0.00001)。
- 联合治疗调节心率(MD=-7.6,95%CI:-9.17至-6.02,P<0.00001)。
- 联合治疗增加尿量(MD=7.26,95%CI:5.00-9.53,P<0.00001),未报告严重不良事件。
关键数值与推荐
- 纳入标准为比较中药联合常规治疗与单用常规治疗失血性休克患者的RCT。
- 效应量为RR或MD及95%CI,采用固定效应模型(RevMan 5.2)进行Meta分析,STATA 12.0评估发表偏倚。
临床怎么用
- 在常规治疗基础上可考虑联合中药治疗失血性休克,但需结合临床实际并关注证据质量低的局限。
局限性
- 纳入试验方法学质量低,分析结果需谨慎解读。
- 需要严格设计、高质量、多中心、大样本试验证实结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chinese herbal medicine (CHM) has been widely used in the treatment of hemorrhagic shock (HS) in China. Many controlled trials have been undertaken to investigate its efficacy. OBJECTIVE: To evaluate the effectiveness and safety of CHM for Hemorrhagic Shock patients. METHODS: We screening the Web of ScienceDirect database, PubMed, the Cochrane Library, EMBASE, China Biomedical Database web (CBM), China National Knowledge Infrastructure (CNKI) and WanFang database (WF), from inception to January 2015. All the randomized controlled trials (RCTs) that compared CHM plus conventional therapy with conventional therapy alone for HS patients were included. Meta-analysis on included studies was performed using fixed-effects model with RevMan 5.2. Risk ratio (RR) or mean difference (MD) with a 95% confidence interval (CI) was used as effect measure. STATA 12.0 was used for publication bias. RESULTS: Fifteen RCTs involving 1076 participants were included in the meta-analysis. CHM combined with conventional therapy was tested to be more effective in reduce mortality (RR=0.24, 95%CI:0.13-0.46, P<0.0001), reduce the incidence of MODS (RR=0.47, 95%CI: 0.34-0.66,P<0.00001), symptomatic improvement: increase blood pressure (BP) (MD=8.83, 95%CI:6.82-10.84,P<0.00001), regulate heart rate (MD=-7.6,95%CI:-9.17 to -6.02,P<0.00001), increase urine volume (MD=7.26, 95%CI:5.00-9.53, P<0.00001), compared with conventional therapy alone. No serious adverse events were reported. CONCLUSIONS: CHM combined with conventional therapy seems to be more effective on HS patients. However, the analysis results should be interpreted with caution due to the low methodological quality of the included trials. Future, the rigorously designed, high methodological quality, multicenter and large-scale trials are needed to confirm these conclusions.
引用
- Wang DL, Lu XG, Guo WX, et al. The effect of Chinese herbal medicine on hemorrhagic shock: A systematic review and meta-analysis. Complement Ther Med. 2016. PMID: 27912961. doi:10.1016/j.ctim.2016.09.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。